NeuMedics is a privately held drug development company formed in Washington State in 2008. Its three co-founders combine more than 60 years of experience in executive management, drug development, and regulatory approvals. The Company has created a proprietary new compound (NM108) that holds great promise as a preventative treatment to delay the onset of Alzheimer’s disease (AD) dementia symptoms.  The data from preliminary studies confirm that NM108 has the potential to become “Lipitor® for the Brain” for as many as eight million at-risk patients in the United States alone.